Semin Thromb Hemost
DOI: 10.1055/s-0041-1733925
Review Article

Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?

Anna Falanga
1  Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
2  Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy
,
Marina Marchetti
1  Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Laura Russo
1  Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
› Author Affiliations
Funding The HYPERCAN study (ClinicalTrials.gov # NCT0262281) is funded by AIRC “5xMILLE” n. 12237 grant from the “Italian Association for Cancer Research (AIRC).”

Abstract

Cancer patients are characterized by hypercoagulable state and an increased rate of thrombotic events, the most common being venous thromboembolism. Several hemostatic pathways that are significantly implicated in mechanisms of thromboembolic disease are also involved in growth, invasion, and metastatic spread of malignant cells as well in tumor-induced neo-angiogenesis. This close connection between cancer and the hemostatic system has prompted numerous studies on the role of alterations in the level plasma biomarkers of the different compartments of hemostasis in predicting cancer prognosis. In this review, we collect the results of several exemplificative studies that have evaluated clotting activation biomarkers in relation to different cancer outcomes with a final emphasis on current research and forthcoming directions in this field.



Publication History

Publication Date:
27 August 2021 (online)

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA